RT Journal Article
SR Electronic
T1 No evidence of significant cross-reactivity between the dengue virus (DENV) and SARS-CoV-2 IgG antibodies
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.19.21255725
DO 10.1101/2021.04.19.21255725
A1 Shurrab, Farah M.
A1 Humaira, Fatima
A1 Al-Absi, Enas S.
A1 Al-Sadeq, Duaa W.
A1 Qotba, Hamda
A1 Yassine, Hadi. M.
A1 Abu-Raddad, Laith J.
A1 Nasrallah, Gheyath K.
YR 2021
UL http://medrxiv.org/content/early/2021/04/22/2021.04.19.21255725.abstract
AB Background Several studies reported serological cross-reaction between DENV and SARS-CoV-2 IgG antibodies using rapid point of care (POC) assays. Limited data are available about cross-reactivity when testing is done using advanced chemiluminescence immunoassay (CLIA) and ELISA assays.Objective This study aims to investigate potential serological cross-reactivity between SARS-CoV-2-IgG and DENV-IgG using CLIA and ELISA assays.Study-design A total of 90 DENV-IgG-ELISA positive and 90 negative pre-pandemic sera were tested for anti-SARS-CoV-2-IgG using the automated CL-900i CLIA assay. Furthermore, a total of 91 SARS-CoV-2-IgG-CLIA positive and 91 negative post-pandemic sera were tested for anti-DENV-IgG using the Novalis ELISA assay.Results The DENV-IgG positive sera had 5 positives and 85 negatives for SARS-CoV-2-IgG. The DENV-IgG negative sera also had 5 positives and 85 negatives for SARS-CoV-2-IgG. No statistically significant difference in specificity between the DENV-IgG positive and DENV-IgG negative sera was found (p-value=1.00). The SARS-CoV-2-IgG positive sera had 43 positives, 47 negatives, and 1 equivocal for DENV-IgG. The SARS-CoV-2-IgG negative sera had 50 positives, 40 negatives, and 1 equivocal for DENV-IgG. No statistically significant difference in the proportion that is DENV-IgG positive between the SARS-CoV-2-IgG positive and SARS-CoV-2-IgG negative sera (p-value=0.58).Conclusions No evidence for cross-reactivity between the DENV and SARS-CoV-2 IgG antibodies was found.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by grant No. RRC-2-032 & UREP19-013-3-001 from the Qatar National Research Fund (a member of Qatar Foundation) and Qatar University internal grant QUERG-CMED-2020-2.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This project was approved by the Institutional Review Boards at Qatar University (QU-IRB 1492-E/21)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe were constrained by our local, internal ethics policies, which entail confidentiality and therefore anonymity with regard to the samples for analysis in studies of this nature. Disclosing raw data will be breaching participant confidentiality requests to access the data should be addressed to the Ethical committee of Qatar University